{"success":true,"data":{"pressRelease":{"id":"81390","rtpr_id":"nACSYXlRFa","ticker":"GRAL","exchange":"NASDAQ","all_tickers":["GRAL"],"title":"Recover Investment Losses: Class Action Initiated Against GRAIL, Inc. (GRAL)","author":"ACCESSWIRE","published_at":"2026-07-06T21:07:00.312Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n6, 2026 / Levi & Korsinsky, LLP announces that a securities class action\nlawsuit has been filed on behalf of investors who purchased or otherwise\nacquired GRAIL, Inc. (NASDAQ:GRAL) securities.\n\nIf you suffered a loss on your GRAIL investment and would like to explore a\npotential recovery under the federal securities laws, Learn about GRAIL Class\nAction (https://pr.report/nelj) or contact Joseph E. Levi, Esq. via email at\njlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of\nexperienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against GRAIL, Inc.\nthat seeks to recover losses of shareholders who were adversely affected by\nalleged securities fraud between May 13, 2025 and February 19, 2026.\n\nCASE DETAILS: According to the complaint, defendants provided overwhelmingly\npositive statements to investors while, at the same time, disseminating\nmaterially false and misleading statements and/or concealing material adverse\nfacts concerning the true state of GRAIL's NHS-Galleri trial following the\nreveal of the top-line results covering the first screening round. Notably, as\ndefendants have since attested, the trial as executed within the three-year\nfollow-up period was insufficient to demonstrate the achievability of a\nreduction in Stage III-IV cancers; defendants disclosed the trial period, and\nthus the screening duration, was apparently insufficient to demonstrate\nwhether the primary endpoint was achievable. Defendants further repeatedly\nrefused to provide detailed topline results or other data from the NHS-Galleri\nstudy, potentially concealing known trendlines which arguably suggested either\na longer timeline would be necessary or otherwise that the probability of\nachieving the statistical reduction in Stage III & IV cancers by the trial's\nend had been reduced.\n\nOn February 19, 2026, GRAIL announced that the \"primary endpoint of\nstatistically significant Stage III-IV reduction was not observed\" in the\nNHS-Galleri Trial. The Company attributed this shortcoming, in part, on\n\"probably need[ing] a longer follow-up time to be able to [compare the study\narms] adequately.\"\n\nFollowing this news, the price of GRAIL's common stock declined dramatically.\nFrom a closing market price of $101.53 per share on February 19, 2026, Grail's\nstock price fell to $50.21 per share on February 20, 2026, a decline of about\n50.55% in the span of just a single day.\n\nWHAT'S NEXT? If you purchased GRAIL stock during the relevant time frame -\neven if you still hold your shares, learn about your rights to seek a recovery\n(https://pr.report/nelk). There is no cost or obligation to participate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/recover-investment-losses-class-action-initiated-against-grail-i-1187153)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSYXlRFa","title":"Recover Investment Losses: Class Action Initiated Against GRAIL, Inc. (GRAL)","author":"ACCESSWIRE","ticker":"GRAL","created":"2026-07-06T21:07:00.312Z","tickers":["GRAL"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July\n6, 2026 / Levi & Korsinsky, LLP announces that a securities class action\nlawsuit has been filed on behalf of investors who purchased or otherwise\nacquired GRAIL, Inc. (NASDAQ:GRAL) securities.\n\nIf you suffered a loss on your GRAIL investment and would like to explore a\npotential recovery under the federal securities laws, Learn about GRAIL Class\nAction (https://pr.report/nelj) or contact Joseph E. Levi, Esq. via email at\njlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of\nexperienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against GRAIL, Inc.\nthat seeks to recover losses of shareholders who were adversely affected by\nalleged securities fraud between May 13, 2025 and February 19, 2026.\n\nCASE DETAILS: According to the complaint, defendants provided overwhelmingly\npositive statements to investors while, at the same time, disseminating\nmaterially false and misleading statements and/or concealing material adverse\nfacts concerning the true state of GRAIL's NHS-Galleri trial following the\nreveal of the top-line results covering the first screening round. Notably, as\ndefendants have since attested, the trial as executed within the three-year\nfollow-up period was insufficient to demonstrate the achievability of a\nreduction in Stage III-IV cancers; defendants disclosed the trial period, and\nthus the screening duration, was apparently insufficient to demonstrate\nwhether the primary endpoint was achievable. Defendants further repeatedly\nrefused to provide detailed topline results or other data from the NHS-Galleri\nstudy, potentially concealing known trendlines which arguably suggested either\na longer timeline would be necessary or otherwise that the probability of\nachieving the statistical reduction in Stage III & IV cancers by the trial's\nend had been reduced.\n\nOn February 19, 2026, GRAIL announced that the \"primary endpoint of\nstatistically significant Stage III-IV reduction was not observed\" in the\nNHS-Galleri Trial. The Company attributed this shortcoming, in part, on\n\"probably need[ing] a longer follow-up time to be able to [compare the study\narms] adequately.\"\n\nFollowing this news, the price of GRAIL's common stock declined dramatically.\nFrom a closing market price of $101.53 per share on February 19, 2026, Grail's\nstock price fell to $50.21 per share on February 20, 2026, a decline of about\n50.55% in the span of just a single day.\n\nWHAT'S NEXT? If you purchased GRAIL stock during the relevant time frame -\neven if you still hold your shares, learn about your rights to seek a recovery\n(https://pr.report/nelk). There is no cost or obligation to participate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/recover-investment-losses-class-action-initiated-against-grail-i-1187153)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-07-06T21:07:00.363608304Z","server_sent_at_ms":1783372020363},"received_at":"2026-07-06T21:07:00.430Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/recover-investment-losses-class-action-initiated-against-grail-i-1187153"},"analysis":{"id":"70502","press_release_id":"81390","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky, LLP announced that a class action lawsuit has been filed against GRAIL, Inc. on behalf of investors who purchased securities between May 13, 2025 and February 19, 2026.\n\nThe complaint alleges defendants made false statements regarding the NHS-Galleri trial's top-line results and refused to disclose detailed data suggesting a longer timeline might be needed.\n\nThis release is a law-firm solicitation for shareholders seeking recovery; it is not a company disclosure or a certified class action settlement.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"post_drop_price":50.21,"prior_close_price":101.53,"stock_drop_percentage":"50.55%"}},"quotedText":"There is no cost or obligation to participate.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Partner"},{"name":"Ed Korsinsky, Esq.","role":"Partner"}],"products":["NHS-Galleri trial"],"companies":[{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"defendant"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$101.53","context":"closing market price on February 19, 2026"},{"amount":"$50.21","context":"stock price on February 20, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Levi & Korsinsky, LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"GRAL"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky, LLP announced that a class action lawsuit has been filed against GRAIL, Inc. on behalf of investors who purchased securities between May 13, 2025 and February 19, 2026.\n\nThe complaint alleges defendants made false statements regarding the NHS-Galleri trial's top-line results and refused to disclose detailed data suggesting a longer timeline might be needed.\n\nThis release is a law-firm solicitation for shareholders seeking recovery; it is not a company disclosure or a certified class action settlement.","key_figures":{"customDimensions":{"post_drop_price":50.21,"prior_close_price":101.53,"stock_drop_percentage":"50.55%"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Partner"},{"name":"Ed Korsinsky, Esq.","role":"Partner"}],"products":["NHS-Galleri trial"],"companies":[{"name":"GRAIL, Inc.","ticker":"GRAL","relationship":"defendant"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$101.53","context":"closing market price on February 19, 2026"},{"amount":"$50.21","context":"stock price on February 20, 2026"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-06T21:08:04.666Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":64218,"modelName":"george-droid-qwen-72b"}}